MarketCap
Facebook
X
Telegram
Tenax Therapeutics Accounts Payables | TENX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Tenax Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 1967 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.04 M | 3.16 M | 2.07 M | 448 K | 860 K | 758 K | 1.66 M | 750 K | 612 K | 728 K | 972 K | 411 K | 977 K | 543 K | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.04 M | 411 K | 1.43 M |
Quarterly Accounts Payables Tenax Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.8 M | 6.35 M | 5.61 M | 562 K | 1.84 M | 3.16 M | 1.58 M | 870 K | 1.08 M | 2.07 M | 135 K | 206 K | 172 K | 448 K | 265 K | 919 K | 1.29 M | 860 K | 776 K | 792 K | 997 K | 758 K | 758 K | 758 K | 758 K | 1.66 M | 1.66 M | 1.66 M | 1.66 M | 750 K | 750 K | 750 K | 750 K | 612 K | 612 K | 612 K | 612 K | 728 K | 728 K | 728 K | 728 K | 972 K | 972 K | 972 K | 972 K | 669 K | 1.65 M | 586 K | 411 K | 808 K | 921 K | 970 K | 977 K | 650 K | 479 K | 835 K | 543 K | - | 782 K | 1.06 M | 889 K |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.8 M | 135 K | 1.18 M |
Accounts Payables of other stocks in the Biotechnology industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
3.62 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
2.08 M | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
1.88 M | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
2.51 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
261 K | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
1.11 M | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
663 K | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
406 K | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
4.43 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
2.4 M | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
1.41 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
1.45 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
4.16 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
1.28 M | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
1.69 M | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
17.7 M | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
32.8 M | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
1.18 M | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
610 K | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
8.69 M | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
5.26 M | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
5.17 M | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
4.94 M | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
10.8 M | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
14.9 M | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.16 M | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
210 M | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
MeiraGTx Holdings plc
MGTX
|
10.1 M | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
462 M | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Catalyst Biosciences
CBIO
|
124 K | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
32.6 M | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
6.04 M | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
2.6 M | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
EyePoint Pharmaceuticals
EYPT
|
10.5 M | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
14.2 M | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
4.64 M | $ 10.12 | 0.4 % | $ 289 M | USA |
|
Foghorn Therapeutics
FHTX
|
4.27 M | $ 2.04 | 2.0 % | $ 128 M | USA |